Switch theme
Sign up to access all valuation multiples
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
2014
163
LTM Revenue $101M
LTM EBITDA -$150M
$2.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Arcellx has a last 12-month revenue of $101M and a last 12-month EBITDA of -$150M.
In the most recent fiscal year, Arcellx achieved revenue of $108M and an EBITDA of -$99.1M.
Arcellx expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Arcellx valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $110M | $108M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$64.1M | -$99.1M | XXX | XXX | XXX |
| EBITDA Margin | -58% | -92% | XXX | XXX | XXX |
| Net Profit | -$189M | -$70.7M | XXX | XXX | XXX |
| Net Margin | -171% | -65% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Arcellx's stock price is $60.
Arcellx has current market cap of $3.3B, and EV of $2.8B.
See Arcellx trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.8B | $3.3B | XXX | XXX | XXX | XXX | $-2.29 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Arcellx has market cap of $3.3B and EV of $2.8B.
Arcellx's trades at 27.4x LTM EV/Revenue multiple, and -18.5x LTM EBITDA.
Analysts estimate Arcellx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Arcellx and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.8B | XXX | XXX | XXX |
| EV/Revenue | 25.8x | XXX | XXX | XXX |
| EV/EBITDA | -28.1x | XXX | XXX | XXX |
| P/E | -30.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -28.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpArcellx's NTM/LTM revenue growth is 10%
Arcellx's revenue per employee for the last fiscal year averaged $0.7M, while opex per employee averaged $1.5M for the same period.
Over next 12 months, Arcellx's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Arcellx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Arcellx and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -2% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -92% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 54% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -82% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.7M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 82% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 146% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 227% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Arcellx acquired XXX companies to date.
Last acquisition by Arcellx was XXXXXXXX, XXXXX XXXXX XXXXXX . Arcellx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Arcellx founded? | Arcellx was founded in 2014. |
| Where is Arcellx headquartered? | Arcellx is headquartered in United States of America. |
| How many employees does Arcellx have? | As of today, Arcellx has 163 employees. |
| Who is the CEO of Arcellx? | Arcellx's CEO is Mr. Rami Elghandour. |
| Is Arcellx publicy listed? | Yes, Arcellx is a public company listed on NAS. |
| What is the stock symbol of Arcellx? | Arcellx trades under ACLX ticker. |
| When did Arcellx go public? | Arcellx went public in 2022. |
| Who are competitors of Arcellx? | Similar companies to Arcellx include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Arcellx? | Arcellx's current market cap is $3.3B |
| What is the current revenue of Arcellx? | Arcellx's last 12-month revenue is $101M. |
| What is the current EBITDA of Arcellx? | Arcellx's last 12-month EBITDA is -$150M. |
| What is the current EV/Revenue multiple of Arcellx? | Current revenue multiple of Arcellx is 27.4x. |
| What is the current EV/EBITDA multiple of Arcellx? | Current EBITDA multiple of Arcellx is -18.5x. |
| What is the current revenue growth of Arcellx? | Arcellx revenue growth between 2023 and 2024 was -2%. |
| Is Arcellx profitable? | Yes, Arcellx is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
